Crinetics Pharma Files 8-K, Confirms Nasdaq Listing

TL;DR

**Crinetics Pharma just filed a routine 8-K, confirming its Nasdaq listing and regulatory compliance.**

AI Summary

Crinetics Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, primarily to disclose its current report status and confirm its registration on the Nasdaq Global Select Market under the trading symbol CRNX. This filing indicates standard compliance with SEC regulations, specifically under Regulation FD Disclosure and Financial Statements and Exhibits. For investors, this matters because it confirms the company's ongoing adherence to public reporting requirements, maintaining transparency and its listing status, which is crucial for liquidity and investor confidence.

Why It Matters

This filing confirms Crinetics Pharmaceuticals' ongoing compliance with SEC reporting, which is essential for maintaining investor trust and its stock's listing on the Nasdaq Global Select Market.

Risk Assessment

Risk Level: low — This is a routine administrative filing with no new material financial or operational information, indicating low risk.

Analyst Insight

This filing is routine and does not present new information that would warrant immediate action. Investors should continue to monitor for substantive news regarding clinical trials, financial performance, or strategic partnerships.

Key Numbers

• $0.001 — Par value per share (The stated par value of Crinetics Pharmaceuticals' common stock.)

Key Players & Entities

• Crinetics Pharmaceuticals, Inc. (company) — the registrant filing the 8-K
• Nasdaq Global Select Market (company) — the exchange where Crinetics Pharmaceuticals' common stock is registered
• CRNX (other) — the trading symbol for Crinetics Pharmaceuticals' common stock
• January 8, 2024 (date) — the date of the earliest event reported and filing date
• $0.001 (dollar_amount) — par value per share of common stock

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share CRNX Nasdaq Global Select

Filing Documents

• d706423d8k.htm (8-K) — 34KB
• d706423dex991.htm (EX-99.1) — 25KB
• g706423ex99_1p10g1.jpg (GRAPHIC) — 397KB
• g706423ex99_1p11g1.jpg (GRAPHIC) — 186KB
• g706423ex99_1p12g1.jpg (GRAPHIC) — 223KB
• g706423ex99_1p13g1.jpg (GRAPHIC) — 285KB
• g706423ex99_1p14g1.jpg (GRAPHIC) — 330KB
• g706423ex99_1p15g1.jpg (GRAPHIC) — 217KB
• g706423ex99_1p16g1.jpg (GRAPHIC) — 379KB
• g706423ex99_1p17g1.jpg (GRAPHIC) — 241KB
• g706423ex99_1p18g1.jpg (GRAPHIC) — 289KB
• g706423ex99_1p19g1.jpg (GRAPHIC) — 367KB
• g706423ex99_1p1g1.jpg (GRAPHIC) — 187KB
• g706423ex99_1p20g1.jpg (GRAPHIC) — 139KB
• g706423ex99_1p2g1.jpg (GRAPHIC) — 591KB
• g706423ex99_1p3g1.jpg (GRAPHIC) — 399KB
• g706423ex99_1p4g1.jpg (GRAPHIC) — 182KB
• g706423ex99_1p5g1.jpg (GRAPHIC) — 271KB
• g706423ex99_1p6g1.jpg (GRAPHIC) — 311KB
• g706423ex99_1p7g1.jpg (GRAPHIC) — 276KB
• g706423ex99_1p8g1.jpg (GRAPHIC) — 290KB
• g706423ex99_1p9g1.jpg (GRAPHIC) — 318KB
• 0001193125-24-003929.txt ( ) — 8282KB
• crnx-20240108.xsd (EX-101.SCH) — 3KB
• crnx-20240108_lab.xml (EX-101.LAB) — 17KB
• crnx-20240108_pre.xml (EX-101.PRE) — 11KB
• d706423d8k_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. During the week of January 8, 2024, Crinetics Pharmaceuticals, Inc. (the "Company," "Crinetics," "we," "us," or "our") will be attending meetings with investors, analysts and others at the 42nd annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 8-11, 2024. Scott Struthers, Ph.D., Founder & Chief Executive Officer of Crinetics, will present a company update on Tuesday, January 9th at 3:45 pm Pacific Time. A live audio webcast of Dr. Struthers' presentation may be accessed on the Events section of the Company's website or directly on the J.P. Morgan virtual meeting platform. During the presentation, the Company will reference the corporate slide presentation attached as Exhibit 99.1 to this Current Report on Form 8-K, which is incorporated herein by reference. The presentation will feature an overview of Crinetics' key priorities and anticipated milestones for 2024. These include: The continued advancement of the Phase 3 PATHFNDR-2 trial of once-daily oral paltusotine in acromegaly. The trial remains on track for topline data readouts in the first quarter of 2024. If successful, Crinetics plans to submit data from its Phase 3 program to regulatory authorities in support of applications seeking approval for the use of paltusotine for all acromegaly patients who require pharmacotherapy, including untreated patients and those switching from other therapies. Efforts to further increase commercial readiness so that the Company can rapidly provide patients in the United States with acromegaly with broad access to once-daily oral paltusotine, if the new drug application is submitted and approved. The continued advancement of the Phase 2 trial of paltusotine in carcinoid syndrome, which remains on track for complete topline data in the first half of 2024 and the initiation of a Phase 3 program in the second half of 2024. The continued advancement of the Phase 2 trials of CRN04894, a

Forward-Looking Statements

Forward-Looking Statements This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this report are forward-looking statements, including statements regarding the plans and timelines for the clinical development of paltusotine, including the therapeutic potential and clinical benefits or safety profile thereof; the expected timing of topline data from the Phase 3 PATHFNDR-2 study of paltusotine in acromegaly and the Phase 2 study of paltusotine in carcinoid syndrome; plans and expected timing of Phase 3 trials of paltusotine in carcinoid syndrome; plans to submit data from the ongoing Phase 3 clinical studies of paltusotine in acromegaly to regulators in support of applications seeking approval for the use of paltusotine in acromegaly patients; the expected timing of a new drug application submission for paltusotine for the treatment or maintenance of treatment of acromegaly in the United States; the potential market opportunity for paltusotine in acromegaly and carcinoid syndrome; the expected timing of initial data from studies of CRN04894 in CAH and Cushing's disease; the potential for any of our ongoing clinical studies to show safety or efficacy. These forward-looking statements speak only as of the date of this report and are subject to a number of known and unknown risks, uncertainties, assumptions, and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, without limitation, initial findings and topline results that we report may change following a more comprehensive review of the data related to the clinical studies and such data may not accurately reflect the complete results

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Corporate Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Crinetics Pharmaceuticals, Inc. Date: January 8, 2024 By: /s/ R. Scott Struthers, Ph. D. R. Scott Struthers, Ph. D. President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR